Dr. Marvin Eng, MD
Claim this profileHenry Ford Hospital
Affiliated Hospitals
Henry Ford Hospital
Banner Good Samaritan
Clinical Trials Marvin Eng, MD is currently running
Edwards PASCAL System
for Tricuspid Regurgitation
This trial tests a new device that fixes a leaky heart valve without surgery in patients who are too risky for traditional surgery. The device helps the valve close properly to stop blood from leaking backward. The first device specifically designed for this purpose is the paravalvular leak device (PLD - Occlutech).
Recruiting
1 award
N/A
6 criteria
Transseptal ViMAC
for Mitral Valve Disease
A prospective multicenter study enrolling high surgical risk patients with severe mitral annular calcification (MAC) and symptomatic mitral valve dysfunction (severe stenosis, ≥ moderate to severe regurgitation, or mixed ≥ moderate stenosis and ≥ regurgitation). There are 2 Arms in this study: 1) "Transseptal (TS) Valve-in-MAC" (ViMAC) Arm, and 2) Natural History of Disease Registry (NHDR) for patients treated with medical treatment only (which includes patients who meet inclusion criteria but can't be treated with transeptal ViMAC due to the presence of anatomical exclusion criteria or other exclusion criteria) and have not had other procedures that may impact outcomes (i.e., alcohol septal ablation or radiofrequency ablation). The study also includes a Registry of Permanently Unassigned" for subjects who undergo preemptive septal ablation procedures (alcohol or radiofrequency) in anticipation of continuing onto ViMAC arm, but are not accepted in the ViMAC Study arm or the patient chooses not to undergo ViMAC procedure.
Recruiting
1 award
N/A
2 criteria
More about Marvin Eng, MD
Clinical Trial Related
7 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Marvin Eng, MD has experience with
- Edwards PASCAL System
- ACURATE Neo2™ Transfemoral TAVR System
- Medtronic CoreValve TAVR System
- Edwards SAPIEN 3 TAVR System
- ACURATE Prime™ Transfemoral TAVR System XL
- Tendyne Mitral Valve System
Breakdown of trials Marvin Eng, MD has run
Mitral Regurgitation
Mitral Valve Regurgitation
Mitral Valve Disease
Von Willebrand Disease
Aortic Stenosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marvin Eng, MD specialize in?
Marvin Eng, MD focuses on Mitral Regurgitation and Mitral Valve Regurgitation. In particular, much of their work with Mitral Regurgitation has involved Stage III patients, or patients who are undergoing treatment.
Is Marvin Eng, MD currently recruiting for clinical trials?
Yes, Marvin Eng, MD is currently recruiting for 2 clinical trials in Detroit Michigan. If you're interested in participating, you should apply.
Are there any treatments that Marvin Eng, MD has studied deeply?
Yes, Marvin Eng, MD has studied treatments such as Edwards PASCAL System, ACURATE neo2™ Transfemoral TAVR System, Medtronic CoreValve TAVR System.
What is the best way to schedule an appointment with Marvin Eng, MD?
Apply for one of the trials that Marvin Eng, MD is conducting.
What is the office address of Marvin Eng, MD?
The office of Marvin Eng, MD is located at: Henry Ford Hospital, Detroit, Michigan 48202 United States. This is the address for their practice at the Henry Ford Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.